A randomized comparative study of lobaplatin and cisplatin combined with etoposide for small cell lung cancer in elder patients

【Objective】To observe the short-term clinical efficacy and the side effects of LE(lobaplatin and etoposide) and EP(cisplatin and etoposide) regimens for advanced small cell lung cancer(SCLC) in elder patients.【Methods】A total of 56 cases of advanced small cell lung cancer were randomized into LE group(28 patients) and EP group(28 patients) according to the hospital diagnosis.Two programs were repeated every 21 days and 2 cycles.The short-term clinical efficacy and the side effects of two groups were evaluated every week.【Results】The response rate in experiment group and control group were 71% and 68% respectively,and disease control rate were 89% and 86% respectively,whereas all the observed effects had no significance(P 0.05).The side-effects were mainly myleosuppression with no statistic differences(P 0.05),However,the side effects of gastrointestinal reaction in the two groups were 21% and 50% respectively,with obvious statistic difference(P 0.05).【Conclusion】LE and EP regimens have similar total effective rate and side effects in patients with SCLC.There is no significant survival advantage for the program of lobaplatin and etoposide as compared with the one with cisplatin and etoposide,but the gastrointestinal reaction in LE is inferior to EP.So the regimen of lobaplatin and etoposide is better tolerated,especially in old patients and the patients of advanced small cell lung cancer who had accepted the treatment of DDP and chemotherapy before.